Open Biosystems Gains Momentum in European RNAi Market
News May 12, 2006
Through this program, CIC bioGUNE has purchased Open Biosystems' whole-genome human retroviral shRNAmir library.
With a commitment to accelerating research processes that lead to innovation, CIC bioGUNE is focused on optimizing its technological and scientific capacities to identify, prevent and cure disease.
Open Biosystems' Open Access Program provides CIC bioGUNE's affiliated researchers with access to a whole-genome retroviral library without imposing heavy financial burdens.
The program also provides CIC bioGUNE with the ability to freely distribute the library within the institution, and a technical support team including scientific site visits. The program also offers an off-site backup for the library.
"Open Biosystems' shRNAmir technology is the most advanced RNAi tool available," said Jose Maria Mato, institute director, CIC bioGUNE.
"As we strive to lead Spain's bioscience research efforts, it is crucial that we utilize the most advanced research tools available. However, like most institutions, we are confined by costs."
"Open Biosystems' Open Access Program is the ideal solution. Our researchers now have access to the most advanced RNAi technology without the costs typically associated with such tools."
Open Biosystems' whole-genome retroviral shRNAmir library design is based on the understanding of natural RNAi pathways.
As a result, CIC bioGUNE researchers can target any gene in the human genome with improved gene knockdown efficiency.
"RNAi is an innovative research tool that is gaining popularity around the world as scientists and researchers realize and witness its value," said Brian Pollock, chief executive officer and co-founder of Open Biosystems.
"By providing broad availability of RNAi resources across whole institutions, the Open Access Program creates a collaboration that encourages and supports scientific advancements. CIC bioGUNE is one of many institutions that can benefit from this approach."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019